Prophylaxis of postoperative nausea and vomiting in elective breast surgery

• Published in: Journal of clinical anesthesia 2011-09, Vol.23 (6), p.461-468
• Main Authors: Voigt, Matthias, MD, Fröhlich, Christian W., MD, Waschke, Klaus F., MD, Lenz, Christian, MD, Göbel, Ulrich, MD, Kerger, Heinz, MD
• Format: Article
• Language: English
• Subjects: Adult; Anesthesia; Anesthesia & Perioperative Care; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Anesthetics, Inhalation - adverse effects; Anesthetics, Intravenous - adverse effects; Anesthetics, volatile; Antiemetic prophylaxis; Antiemetics - therapeutic use; Biological and medical sciences; Breast - surgery; Confidence intervals; Dexamethasone; Dexamethasone - therapeutic use; Dimenhydrinate; Dimenhydrinate - therapeutic use; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Haloperidol - therapeutic use; Humans; Indoles - therapeutic use; Intubation; Male; Medical sciences; Nausea; Pain Medicine; Postoperative nausea and vomiting; Postoperative Nausea and Vomiting - epidemiology; Postoperative Nausea and Vomiting - prevention & control; Postoperative period; Preanesthetic Medication; Prospective Studies; Risk Factors; Statistical analysis; Surgery; Total intravenous anesthesia; Tropisetron; Vomiting
• ISSN: 0952-8180; 1873-4529
• DOI: 10.1016/j.jclinane.2011.01.005

Abstract Study Objective To evaluate strategies to treat postoperative nausea and vomiting (PONV) in patients undergoing elective breast surgery. Design Prospective, randomized, double-blinded, placebo-controlled trial. Setting University-affiliated hospital. Patients 480 patients with risk factors for PONV. Interventions Patients were randomized to three groups to receive an antiemetic prophylactic combination of haloperidol and tropisetron (Group HT), dimenhydrinate and dexamethasone (Group DD), or no prophylaxis (Group P). Anesthesia was maintained with volatile anesthesia (desflurane or sevoflurane) and fentanyl or total intravenous anesthesia (TIVA). Measurements Incidence of nausea, emesis, or both in the early (0 - 2 hrs) and late (2 - 24 hrs) postoperative periods were recorded, as were the number of episodes and the time of each occurrence; and patient assessment of the PONV experience on a scale comparable to a numeric rating scale (NRS). Main Results Both antiemetic combinations significantly reduced PONV incidence. In patients who received no prophylaxis, PONV incidence was 48.2% in patients given volatile anesthetics and 43.8% in those who received TIVA. PONV incidence was 17.5% in the Group HT patients who received volatile anesthetics, and 25% in the Group HT patients who received TIVA. PONV incidence was 11.4% in Group DD patients given volatile anesthetics, and 15% in Group DD patients receiving TIVA. TIVA reduced the incidence of PONV in the early postoperative period (0-2 hrs), but increased PONV incidence in the late period (2-24 hrs). Patients given TIVA with propofol and remifentanil intraoperatively required more opioids postoperatively than patients given volatile anesthetics. Conclusion The frequency of PONV was reduced significantly with both antiemetic combinations.